Platinum-resistant Ovarian Cancer Recruiting Phase 1 / 2 Trials for Pembrolizumab (DB09037)

Also known as: Platinum drug resistant Ovarian cancer / Platinum-resistant Ovarian Cancer (PROC) / Platinum Resistant Ovarian Cancer

DBCOND0068919 (Platinum-resistant Ovarian Cancer)Recruiting1 / 2 IdentifierTitlePurposeDrugs
NCT05081609A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or Chemotherapy or TransCon TLR7/8 Agonist in Adult Participants With Locally Advanced or Metastatic Solid Tumor MalignanciesTreatment